Table 2.

Uni- and multivariate Cox regression analysis

Variables	OS			PFS			TTS
	Univariate	Multivariate		Univariate	Multivariate		Univariate	Multivariate
	p value	p value	HR (95% CI)	p value	p value	HR (95% CI)	p value	p value	HR (95% CI)
Cinical metastatic status (OPD, palliative intent)	0.006	0.002	2.03 (1.30–3.17)	0.002	0.334		0.053	0.938	1.0 (0.56–1.81)
Initial stage (I–IV)	0.567	–	–	0.402			0.561
Metastatic development (synchronous vs. metachronous)	0.802	–	–	0.895			0.653
Previous lines of systemic treatment (1 vs. > 1)	0.166	0.109	–	0.048	0.033	1.7 (1.05–2.77)	0.093	0.152	1.57 (0.84–2.92)
Metastatic burden (1, 2–5, 6–10, > 10)	0.461	–	–	0.062	0.759		0.051	0.686	1.10 (0.741.64)
Affected organs (1 vs. > 1)	0.03	0.633	–	0.004	0.023	2.04 (1.10–3.79)	0.026	0.031	2.53 (1.09–5.89)
Location of metastases (cranial vs. extracranial)	0.201	0.827	–	0.155	0.757		0.48
Histology subtype (SqCC, ADC, LCNEC, adenosquamous, unknown)	0.952	–	–	0.554			0.447
Gene mutation (yes vs. no)	0.834	–	–	0.992			0.696
Status of primary tumor (controlled vs. progressive)	0.973	–	–	0.701			0.824
Targeted therapy (IT, TT, AAT)	0.855	–	–	0.424			0.64
SRT location (cranial, extracranial, both)	0.25	–	–	0.149	0.571		0.767
Number of SRT treated metastases (1–5)	0.642	–	–	0.993			0.509
Start targeted therapy (before, during, after SRT)	0.239	–	–	0.436			0.299
Targeted therapy paused during SRT (yes vs no)	0.645	–	–	0.734			0.104	0.393	1.32 (0.75–2.34)

p < 0.05 is significant

HR  hazard ratio, CI confidence interval, TT targeted therapy, IT immunotherapy, AAT antiangiogenic therapy, PARPi  PARP-inhibitor